[Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer].
Moriwaki
Toshikazu
T
Dept of Internal Medicine, National Hospital Organization Shikoku Cancer Center.
Hyodo
Ichinosuke
I
Nishina
Tomohiro
T
Nasu
Junichirou
J
Hidaka
Satoru
S
Kajiwara
Takeshi
T
Tsuzuki
Takao
T
Hirao
Ken
K
Tsubouchi
Eiji
E
Yamauchi
Yusuke
Y
Hirasaki
Shoji
S
Masumoto
Toshikazu
T
Tanada
Minoru
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine